Navigation Links
Erection Drug Was Not Useful to Two-Thirds of Its Users

According to a large-scale study published in the July issue of the urology journal BJU International, nearly two-thirds of patients have discontinued the use of Uprima// , a drug known to treat problems of erection. The users were not happy with the success rates of this drug.

And 70 per cent of family doctors who expressed an opinion using an official National Health Service (NHS) drug feedback form felt the drug wasn't effective.

Researchers at the UK's Drug Safety Research Unit and University of Portsmouth analysed prescribing data for 11,185 patients seen by NHS family doctors.

The data was gathered from official Green Form Questionnaires that ask doctors to record any significant events recorded in a patient's notes after prescribing newly marketed medicines.

Key findings included:

?65 per cent of doctors said their patient stopped taking Uprima because they felt it wasn't effective and 14 per cent said the patient didn't request a further prescription. (68 per cent of GPs responded to the question).
?Further analysis showed that 59 per cent of patients who didn't find it effective stopped taking Uprima after a month and a further 23 had joined them by month two. (Timescale information was recorded for 79 per cent of patients who judged the drug ineffective).
?70 per cent of doctors said they didn't think the drug was effective and 30 per cent said it was. (65 per cent of GPs responded to the question)
?28.5 per cent of the total patient sample had a history of diabetes, 18.8 per cent had heart disease and 37.2 per cent had tried Viagra. 7.5 per cent were receiving both Uprima and nitrate therapy for angina.
?The most common adverse drug reactions were headache and nausea, in line with the clinical trials and as listed in the Summary of Product Characteristics by the manufacturers.
?The average age of the subjects was 61 and all but eight were male. Three of the women were prescribed Uprima for decreased libido, pain and sexual arousal problems. Prescribing information was not provided for the other five.
?Most patients (99 per cent) received the manufacturer's recommended dose of 2-3mg, with the remainder receiving between 4-12mg. (Starting dose information was completed on 79 per cent of forms).
?99 deaths (just under one per cent of the total sample) were recorded on the forms. The most frequently reported cause of death was heart attack (27 patients), followed by heart disease (nine) and lung cancer (five). In 21 cases the cause of death could not be established by the researchers.
The 11,185 forms covered patients who were first prescribed Uprima between October 2001 - three months after the drug was launched in the UK - and December 2002. Just over 21,000 Questionnaires were issued and 57 per cent of GPs responded.

At least six months after the first prescription for Uprima was issued for each patient, their family doctor was sent a Green Form Questionnaire that requested details about the patient's age and sex and their use of Uprima.

They were also asked to record any significant events that had occurred since the patient was prescribed Uprima, such as suspected drug reactions, unexpected deterioration or improvement in the patient's condition, referral to a specialist or any clinically important changes in laboratory tests.

The form also included questions on diseases commonly associated with erectile dysfunction - such as diabetes and heart disease - together with previous use of similar drugs and co-prescribing of medication for angina.

"Prescription-Event Monitoring provides surveillance on a national scale after new drugs are launched" explains lead researcher Professor Saad Shakir.

"Because family doctors are not approached before the decision to treat a patient has been made, they are not subject to detailed inclusion or exclusion criteria. The decision to prescribe is made purely as a result of their clinical knowledge of the patient and the drug involved.

"The result is real world clinical data that provides information of illness and death in patients treated with newly marketed drugs - a valuable tool in drug safety assessment."

(Source: Eurekalert)

Related medicine news :

1. Young Men Treating Erection Problems without Doctors Prescription
2. Useful Cancer drug stops tumour blood supply
3. Useful drug for stem cell transplant problem
4. Useful device makes spinal surgery safer
5. The Drug Tetrathiomolybdate Found To Be Useful For Various Diseases
6. Calcium Supplements May Not Be Useful After A Certain Threshold Is Achieved
7. Viagra May Be Useful For Serious Lung Disease
8. Radiologists Find New CT Scans Useful
9. Antiviral Drugs May Be Useful For Easing Shingles Pain
10. Anti-Parasitic Drugs Useful in Reducing Damages of Congenital Toxoplasmosis
11. Internet Searches Fail To Give Useful Information To Cancer Patients
Post Your Comments:

(Date:11/30/2015)... ... November 30, 2015 , ... ... of the leading plastic surgery practices in Florida, is proud to announce that ... for surgical innovations giant Ethicon Inc., a Johnson & Johnson Company. , Ethicon ...
(Date:11/30/2015)... (PRWEB) , ... November 30, ... ... (AIS) is pleased to announce the speakers for “Value-Based Payer-Provider Partnerships: Three ... learned from three innovative value-based care arrangements: Essentia Health and UCare, MissionPoint ...
(Date:11/30/2015)... ... , ... Sikka Software announced today that they are showcasing the Sikka Software ... complex business decisions by providing the tools and information they need to grow their ... procedures customized by zip code. , The Sikka Software Ecosystem includes over 32 ...
(Date:11/30/2015)... ... November 30, 2015 , ... The successful filing of an Investigational ... it is so important to this key industry segment, Regis Technologies has decided to ... on December 4th at 11am EST. , Federal law does not allow new drugs ...
(Date:11/30/2015)... EMIGSVILLE, PA (PRWEB) , ... November 30, 2015 ... ... (CCMS) software provider, has verified that their Vasont Universal Integrator (VUI) extension unites ... handle creating, editing, and managing content as a continuous process with the latest ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)...  Hanger, Inc. (NYSE: HGR ) (the "Company") ... of its previously announced consent solicitation (as amended and ... principal amount 7⅛% Senior Notes due 2018 (the "Notes") ... payable pursuant to the Consent Solicitation, (ii) the proposed ... expiration date of the Consent Solicitation.    ...
(Date:11/30/2015)... 2015  Novartis will demonstrate the strength of its ... American Society of Hematology (ASH) Annual Meeting. Presentations will ... as supportive care, including key findings in rare and ... The ASH Annual Meeting will be held December 5-8 ... Novartis Oncology . "We will be presenting encouraging overall ...
(Date:11/30/2015)... , Nov. 30, 2015   VolitionRx Limited (NYSE ... diagnostic tests for a broad range of cancer types and ... LD Micro Conference, which will be held December 1 - 3 ... from VolitionRx will be David Kratochvil , Chief Financial ... of Investor Relations. ® blood-based tests for ...
Breaking Medicine Technology: